Literature DB >> 10606305

Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis.

T Koike1, S Ohara, H Sekine, K Iijima, K Kato, T Shimosegawa, T Toyota.   

Abstract

OBJECTIVE: Although it is widely accepted that Helicobacter pylori (H. pylori) infection is an important cause of atrophic gastritis, few studies have examined the relationship between H. pylori-induced atrophic gastritis and the occurrence of reflux esophagitis. The present study was aimed to examine the relationship between H. pylori infection, atrophic gastritis, and reflux esophagitis in Japan.
METHODS: A total of 175 patients with reflux esophagitis were compared with sex- and age-matched 175 control subjects. Diagnosis of H. pylori infection was made by gastric mucosal biopsy, rapid urease test, and serum IgG antibodies. Severity of atrophic gastritis was assessed by histology and serum pepsinogen I/II ratio.
RESULTS: H. pylori infection was found in 59 (33.7%) patients with reflux esophagitis, whereas it was found in 126 (72.0%) control subjects. The grade of atrophic gastritis was significantly lower in the former than in the latter. Among the H. pylori-positive patients, atrophic gastritis was milder in the patients with reflux esophagitis than in the patients without it.
CONCLUSIONS: These findings suggest that most cases of reflux esophagitis in Japan occur in the absence of H. pylori infection and atrophic gastritis, and it may also tend to occur in patients with milder gastritis even in the presence of H. pylori infection. Therefore, H. pylori infection may be an inhibitory factor of reflux esophagitis through inducing atrophic gastritis and concomitant hypoacidity.

Entities:  

Mesh:

Year:  1999        PMID: 10606305     DOI: 10.1111/j.1572-0241.1999.01593.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  33 in total

1.  Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Kazuro Ikawa; Norifumi Morikawa; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

2.  Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.

Authors:  José L Calleja; Manuel Suarez; Alberto Herreros De Tejada; Angel Navarro
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

3.  Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia.

Authors:  Yoshikazu Kinoshita; Hiroto Miwa; Katsuyuki Sanada; Koji Miyata; Ken Haruma
Journal:  J Gastroenterol       Date:  2013-05-08       Impact factor: 7.527

Review 4.  Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review.

Authors:  Anan Raghunath; A Pali S Hungin; David Wooff; Susan Childs
Journal:  BMJ       Date:  2003-04-05

Review 5.  Gender difference in gastro-esophageal reflux diseases.

Authors:  Kiyotaka Asanuma; Katsunori Iijima; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

6.  Helicobacter pylori status and esophagogastroduodenal mucosal lesions in patients with end-stage renal failure on maintenance hemodialysis.

Authors:  Tomohiko Moriyama; Takayuki Matsumoto; Katsuya Hirakawa; Hirofumi Ikeda; Kazuhiko Tsuruya; Hideki Hirakata; Mitsuo Iida
Journal:  J Gastroenterol       Date:  2010-01-19       Impact factor: 7.527

7.  Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial.

Authors:  J C Y Wu; F K L Chan; J Y L Ching; W-K Leung; Y Hui; R Leong; S C S Chung; J J Y Sung
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

8.  Helicobacter pylori eradication does not exacerbate gastro-oesophageal reflux disease.

Authors:  P Malfertheiner
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

9.  Comparing the acid-suppressive effects of three brands of generic lansoprazole with the original: pharmacokinetic bioequivalence tests do not necessarily guarantee pharmacodynamic equivalence.

Authors:  Tomohiko Shimatani; Seiko Hirokawa; Yumiko Tawara; Kazuko Hamai; Mutsuko Matsumoto; Susumu Tazuma; Masaki Inoue
Journal:  Dig Dis Sci       Date:  2008-12-18       Impact factor: 3.199

10.  Increased Helicobacter pylori-associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase.

Authors:  R Chaturvedi; T de Sablet; M Asim; M B Piazuelo; D P Barry; T G Verriere; J C Sierra; D M Hardbower; A G Delgado; B G Schneider; D A Israel; J Romero-Gallo; T A Nagy; D R Morgan; T Murray-Stewart; L E Bravo; R M Peek; J G Fox; P M Woster; R A Casero; P Correa; K T Wilson
Journal:  Oncogene       Date:  2014-09-01       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.